Delving into the Latest Updates on Apatinib Mesylate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Apatinib, Rivoceranib, Rivoceranib mesilate

+ [5]

Target

VEGFR2

Action

antagonists

Mechanism

VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases+ [5]

Active Indication

Germline BRCA-mutated, HER2-negative metastatic breast cancerHepatocellular CarcinomaGastroesophageal junction adenocarcinoma+ [43]

Inactive Indication

Adenoid Cystic CarcinomaAdvanced biliary tract cancerAdvanced cancer+ [46]

Originator Organization

Advenchen Laboratories LLC

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.Shanghai Shengdi Pharmaceutical Co., Ltd.

Inactive Organization

Elevar Therapeutics, Inc.

Bukwang Pharmaceutical Co., Ltd.

HRYZ (Shanghai) Biotech Co., Ltd.

License Organization

QureBio Ltd.

Bukwang Pharmaceutical Co., Ltd.

Elevar Therapeutics, Inc.

+ [6]

Drug Highest PhaseApproved

First Approval Date

China (17 Oct 2014),

Gastroesophageal junction adenocarcinomastomach adenocarcinoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), National Science and Technology Major Project (China), Special Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O4S

InChIKeyFYJROXRIVQPKRY-UHFFFAOYSA-N

CAS Registry1218779-75-9

Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit. Building upon these observations, this study evaluated the potential synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor and examined the mechanistic basis for their interaction in breast cancer. Notably, we found that this regimen could significantly suppress the proliferation, migration, and invasion of MCF-7 and MDA-MB-231 cells, and promote cell apoptosis. In addition, the levels of p-ERK, NF-κB, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.

01 Mar 2026·BIOORGANIC CHEMISTRY

Effect of apatinib on albendazole metabolism in vitro and in vivo

Article

Author: Xia, Hailun ; Fu, Haoxin ; Cao, Lu ; Lin, Weihong ; Li, Ruibin ; Wang, Peiqi ; Xu, Ren-Ai ; Wu, Jun

Albendazole is a broad-spectrum antiparasitic benzimidazole and has potential for the treatment of tumors. The aim of this study was to investigate the potential inhibitory effects of 77 drugs on the metabolism of albendazole, and further to elaborate the inhibitory mechanism of apatinib on albendazole metabolism in vitro and in vivo, where the concentrations of albendazole and its metabolites were detected using an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay. In vitro results showed that 10 drugs inhibited albendazole metabolism by more than 80%, with the half-maximal inhibitory concentrations (IC₅₀) of apatinib in rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP3A4 (rCYP3A4) being 0.47, 5.53 and 2.01 μM, respectively. Moreover, the inhibition of albendazole by apatinib was non-time-dependent. In addition, the inhibitory mechanisms were mixed consisting of non-competitive and un-competitive for RLM, and competitive and non-competitive for HLM and rCYP3A4. Pharmacokinetic parameters in Sprague-Dawley rats showed that apatinib caused significant increases in AUC_(0-t), AUC_(0-∞), C_max, T_max and t_1/2, while a significant decrease in CL_z/F for albendazole. For the metabolites albendazole sulfoxide and hydroxyalbendazole, apatinib caused significant increases in AUC_(0-t), AUC_(0-∞), and T_max, while a significant decrease in CL_z/F. In summary, apatinib could inhibit the metabolism of albendazole in vitro and in vivo, so albendazole should be closely monitored for adverse effects when used in combination with apatinib and discontinued if necessary.

01 Mar 2026·Biochemistry and Biophysics Reports

Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide

Article

Author: Qi, Shaopei ; Duan, Qianqian ; Li, Cheng ; Xue, Fengjun ; Ge, Jingjing ; Zhao, Chi ; Zhang, Junping ; Zhang, Qin ; Kong, Chenchen

Apatinib in combination with temozolomide (TMZ) has achieved reasonable clinical efficacy in the treatment of recurrent glioblastoma (rGBM), however, there are currently no clear biomarkers related to clinical efficacy or prognosis. Our retrospective study was to investigate tumor microenvironment (TME) features at the gene expression level that are associated with response and long survival benefit of rGBM treated with apatinib and TMZ. We enrolled 22 rGBMs treated with apatinib in combination with TMZ and collected their tissue samples for RNA transcriptome analysis by the Nanostring nCounter platform. The response group had 40 differentially expressed genes compared to the non-response group, with significantly up-regulated expression of genes related to endothelial cells and apoptosis. Enrichment analysis revealed that signaling pathways related to cell proliferation were down-regulated in the response group. In terms of prognosis, there were 16 differential expressed genes in the long-survival benefit group compared with the short-survival benefit group, and four tumor progression-associated genes were also down-regulated in response group expression. Hypoxia related-genes was significantly up-regulated in the long survival benefit group. Enrichment analysis showed that genes related to cell proliferation were also down-regulated in the long-survival benefit group, while the expression of signaling pathway genes related to cell activation, and immune response was significantly up-regulated. Our study suggests that the combination of apatinib and TMZ may potentially provide clinical benefits in treating rGBM by modulating genes associated with cell proliferation, promoting apoptosis, regulating hypoxia, and enhancing immune response within the tumor microenvironment.

107

News (Medical) associated with Apatinib Mesylate

31 Mar 2026

·allsci.com

Lancet: Chia Tai’s benmelstobart and anlotinib combo outperforms pembrolizumab in lung cancer trial

Researchers across 79 centers in China reported that a combination regimen of programmed death-ligand 1 (PD-L1) inhibitor benmelstobart plus the multi-kinase inhibitor anlotinib produced statistically significant improvements in progression-free survival over pembrolizumab monotherapy in PD-L1-positive, driver gene-negative advanced non-small-cell lung cancer (NSCLC), according to the CAMPASS Phase III trial. The results were published in The Lancet Oncology. The trial, funded by Chia Tai Tianqing Pharmaceutical Group, enrolled 531 patients and represents one of the first randomized Phase III datasets to demonstrate head-to-head superiority over pembrolizumab in this setting. Chia Tai is responsible for discovering benmelstobart and development in Greater China, while US-based biotech Apollomics partnered with the China-based firm for rights outside China. Pembrolizumab monotherapy has held a dominant position as first-line treatment for PD-L1-positive advanced NSCLC since its approval based on the KEYNOTE-024 and KEYNOTE-042 trials. However, a substantial proportion of patients progress within a year, and response rates in the broader PD-L1-positive population—defined as tumor proportion score (TPS) of 1% or greater—remain around 30% to 40%. The CAMPASS trial was designed to test whether adding anlotinib, a multi-target anti-angiogenic tyrosine kinase inhibitor, to the PD-L1-targeted benmelstobart could improve outcomes without the addition of chemotherapy. The CAMPASS results The trial randomized patients 2:1, with 354 receiving benmelstobart plus anlotinib and 177 receiving pembrolizumab plus placebo. Patients were aged 18 to 75 years, had an ECOG performance status of 0 or 1, and had no targetable EGFR or ALK mutations. Both squamous and non-squamous histologies were included. Enrollment ran from August 2021 through December 2022 across 79 sites in China. The primary endpoint was progression-free survival assessed by blinded independent central review per RECIST v1.1. Median PFS in the experimental arm was not reached at the time of analysis, compared with 8.9 months in the pembrolizumab arm. The hazard ratio was 0.51 (95% CI: 0.39–0.67; p<0.0001). The 12-month PFS rate was approximately 60% with benmelstobart plus anlotinib versus approximately 40% with pembrolizumab. The PFS benefit was consistent across prespecified subgroups, including patients with TPS 1%–49% and ≥50%, as well as across squamous and non-squamous histologies. Overall survival data, while still maturing with both medians not yet reached, showed a hazard ratio of 0.62 (95% CI: 0.44–0.88; p0.007), indicating an early OS signal in favor of the combination. The objective response rate was approximately 63% in the experimental arm versus 39% in the pembrolizumab arm, a statistically significant difference. The mechanistic rationale for the combination centers on the relationship between tumor angiogenesis and immune suppression. Tumors upregulate VEGF signaling to promote vascular growth, but this process also creates an immunosuppressive microenvironment by reducing T-cell infiltration and promoting regulatory T-cell accumulation. Anlotinib inhibits VEGFR, FGFR, PDGFR, and c-Kit, which normalizes tumor vasculature and is thought to improve T-cell trafficking into the tumor. Benmelstobart then blocks the PD-1/PD-L1 axis, reactivating cytotoxic T-cells within a more accessible microenvironment. The hypothesis is that anti-angiogenic therapy potentiates checkpoint inhibition by making tumors more immunologically permissive, rather than relying on checkpoint blockade alone. The safety profile reflected the dual-agent mechanism. Grade 3 or higher treatment-related adverse events occurred in approximately 60% of patients in the benmelstobart plus anlotinib arm, compared with approximately 35% in the pembrolizumab arm. Anlotinib-related toxicities, particularly hypertension and proteinuria, accounted for a meaningful share of the higher adverse event burden. Treatment discontinuation rates were higher in the experimental arm, however, no new or unexpected safety signals were identified. The investigators characterized the toxicity as manageable with dose modifications. Research context The CAMPASS regimen represents one among several competing approaches to the same problem. Akeso’s ivonescimab, a bispecific antibody targeting both PD-1 and VEGF within a single molecule, reported superiority over pembrolizumab in the HARMONi-2 Phase III trial in 2024 in a Chinese PD-L1-positive NSCLC population. Summit Therapeutics holds ex-China rights to ivonescimab, and the asset has attracted considerable attention as a potential pembrolizumab alternative in the first-line setting. The bispecific format is mechanistically adjacent to the CAMPASS combination but consolidates both activities into one molecule, which may carry pharmacokinetic and dosing advantages. Other China-developed IO combinations—including camrelizumab plus apatinib from Jiangsu Hengrui and sintilimab plus anlotinib from Innovent—are also in late-stage evaluation in overlapping populations. Roche’s atezolizumab plus bevacizumab plus chemotherapy (IMpower150) is approved in non-squamous NSCLC but includes cytotoxic chemotherapy, a distinction that the CAMPASS regimen avoids. The chemotherapy-free design is a feature it shares with the ivonescimab approach, with both positioning against pembrolizumab monotherapy in PD-L1-positive advanced NSCLC. The CAMPASS dataset was generated entirely in China, which carries implications for regulatory and commercial strategy. The trial population reflects a Chinese clinical context, and generalizability to Western populations will require additional data or bridging studies before regulatory submissions outside China. The benmelstobart program is also being evaluated in extensive-stage small-cell lung cancer, where a Phase III trial published in Nature Medicine in 2024 suggests Chia Tai Tianqing is pursuing a broader oncology footprint for the combination platform. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultDrug Approval

29 Jan 2026

·elevartx.com

Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy

Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics Fort Lee, N.J., Jan. 29 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that Dong-Gun (DG) Kim has been appointed its Chief Executive Officer. He will concurrently retain his roles as CEO of HLB US and CEO of Immunomic Therapeutics, Inc., both affiliated companies within HLB Group. At Elevar, DG Kim replaces Dr. Bryan Kim, who will remain CEO of HLB Group’s Verismo Therapeutics, Inc. With Elevar having this week submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration for its top two developmental drugs, the transition allows Bryan Kim to now solely focus on his role with Verismo, which expects to reach several important milestones in the coming year. On January 23, 2026, Elevar submitted an NDA for the combination of its drug candidate rivoceranib, a VEGFR-TKI, and Hengrui Pharma’s camrelizumab, an anti-PD-1 antibody, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). HCC is the most common type of liver cancer. Elevar also submitted an NDA on January 27, 2026, for its investigational drug lirafugratinib as a second-line treatment option for cholangiocarcinoma (CCA) with fibroblast growth factor receptor (FGFR2) fusions or rearrangements. CCA is also known as bile duct cancer. “Bryan Kim has done an exemplary job steering Elevar through the regulatory and developmental steps leading to NDAs for both the rivoceranib-camrelizumab combination in the liver cancer arena and lirafugratinib as a bile duct cancer therapy,” said DG Kim, an Elevar board member since 2020. “With this critical phase completed, I look forward to executing on our commercialization strategy while simultaneously working to meet any requests from the FDA during its review of these important applications.” DG Kim previously served as CEO of HLB Co. Ltd. Prior to that, he spent more than 30 years as a specialist in mergers & acquisitions, corporate finance and investment management at leading corporations and professional firms (law, investment banking and private equity) both in the U.S. and Korea. He holds an A.B. in Physics from Harvard College and a J.D. from Harvard Law School. For more information about Elevar, visit ElevarTX.com About Elevar Therapeutics Elevar Therapeutics, Inc. is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. A subsidiary of HLB Group based in Fort Lee, New Jersey, Elevar’s expertise is rooted in oncology and grounded in compassion. Our team of experienced scientists and industry leaders is highly focused on identifying and developing medicines for complex yet under-treated health conditions, with a shared goal of making a meaningful difference in the lives of patients. For more information, follow us on LinkedIn and Twitter or visit ElevarTX.com. Media Contact: Rosemary Ostmann RoseComm rostmann@rosecomm.com (201) 615-7751

Executive ChangeNDA

04 Dec 2025

·www.globenewswire.com

Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology

Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement versus sorafenib, a standard first-line treatment for uHCC Elevar plans to resubmit its new drug application for camrelizumab/rivoceranib combination therapy in January 2026 Dec. 03, 2025 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the final analysis of its Phase 3 CARES-310 study was published in The Lancet Oncology. The study assessed the efficacy and safety of the combination of Elevar’s drug candidate rivoceranib, an oral TKI, and camrelizumab, a PD-1 inhibitor, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). In the randomized, open-label, international trial (NCT03764293), which included 543 patients at 95 study sites across 13 countries/regions, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement versus sorafenib (median overall survival of 23.8 vs. 15.2 months), a standard first-line treatment for uHCC, and a manageable safety profile. Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026. "Having our Phase 3 study final analysis published in a prestigious journal such as The Lancet Oncology is momentous for Elevar Therapeutics and, even more so, for the global liver cancer patient community,” said Bryan Kim, chief executive officer of Elevar. “The data clearly showed the potential of our combination treatment of camrelizumab and rivoceranib, as it significantly improved survival compared to the standard treatment option. This is evidence that our hard work developing better therapies for patients with few options is paying off. We're proud of everyone on our team and our partners for hitting this milestone, and we’re focused on getting this promising treatment to patients everywhere as soon as possible." Between June 28, 2019, and March 24, 2021, 543 patients (457 [84%] males; 450 [83%] were Asian) were randomly assigned to receive camrelizumab-rivoceranib (n=272) or sorafenib (n=271). At final analysis on June 14, 2023, the median follow-up was 22.1 months (IQR 11.9-30.3) in the camrelizumab-rivoceranib group and 14.9 months (7.2-28.3) in the sorafenib group. Median overall survival was 23.8 months (95% CI 20.6-27.2) with camrelizumab-rivoceranib and 15.2 months (13.2-18.5) with sorafenib (hazard ratio [HR] 0.64 [95% CI 0.52-0.79]; one-sided p<0.0001). Median progression-free survival was 5.6 months (95% CI 5.5-7.4) with camrelizumab-rivoceranib and 3.7 months (95% CI 3.1-3.7) with sorafenib (HR 0.54 [95% CI 0.44-0.67]; one-sided p<0.0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (104 [39%] of 272 patients in the camrelizumab-rivoceranib group vs. 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysesthesia syndrome (33 [12%] vs. 42 [16%]), increased aspartate aminotransferase (47 [17%] vs. 14 [5%]), and increased alanine aminotransferase (38 [14%] vs. 8 [3%]). Treatment-related serious adverse events were reported in 69 (25%) patients in the camrelizumab-rivoceranib group and 18 (7%) patients in the sorafenib group. Treatment-related deaths occurred in one patient each in the camrelizumab-rivoceranib group (multiple organ dysfunction syndrome) and sorafenib group (respiratory failure and circulatory collapse). Hepatocellular Carcinoma (HCC) is the most common type of liver cancer and most frequently develops in people with chronic underlying liver inflammation, which may be from viral and non-viral causes. HCC typically has a poor prognosis with limited treatment options and continues to be a diagnosis with an ongoing urgent medical need. More than 800,000 people worldwide are diagnosed with liver cancer each year and it is also a leading cause of cancer deaths, accounting for more than 700,000 annually, according to the American Cancer Society. Rivoceranib, a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR), a primary pathway for tumor angiogenesis. VEGFR inhibition is a clinically validated target to limit tumor growth and disease progression. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications. Ongoing clinical studies include uHCC (in combination with camrelizumab), gastric cancer (as a monotherapy and in combination with paclitaxel), adenoid cystic carcinoma (as a monotherapy) and colorectal cancer (in combination with Lonsurf®). Rivoceranib was the first TKI approved in gastric cancer in China (November 2014). It is also approved in China in combination with camrelizumab as a first-line treatment for uHCC (January 2023). The drug has been studied in more than 6,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs and VEGF inhibitors. Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), in adenoid cystic carcinoma (U.S.) and in uHCC (U.S. and EU). Elevar Therapeutics, Inc. holds the global rights (excluding China) to rivoceranib and has partnered for its development and marketing with HLB-LS in South Korea. Rivoceranib, under the name apatinib, is also approved in China for advanced gastric cancer and in second-line advanced HCC by the Chinese-territory license-holder, Jiangsu Hengrui Pharmaceuticals Company Ltd., (Hengrui Pharma), under the brand name Aitan®. Camrelizumab (SHR-1210) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers. Camrelizumab is developed by Hengrui Pharma and has been studied in more than 5,000 patients. Currently, 50 clinical trials are underway in a broad range of tumors (including liver cancer, lung cancer, gastric cancer and breast cancer, etc.) and treatment settings. Camrelizumab, under the brand name AiRuiKa®, is currently approved for eight indications in China, including monotherapy for the treatment of HCC (second-line), in combination with rivoceranib as a treatment for uHCC (first-line), relapsed/refractory classic Hodgkin’s lymphoma (third-line), esophageal squamous cell carcinoma (second-line) and nasopharyngeal carcinoma (third-line or further) and in combination with chemotherapy for the treatment of non-small cell lung cancer (non-squamous and squamous), esophageal squamous cell carcinoma and nasopharyngeal carcinoma in the first-line setting. The U.S. Food and Drug Administration granted Orphan Drug Designation to camrelizumab for advanced HCC in April 2021 and by the EMA in August 2024. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultOrphan DrugDrug ApprovalImmunotherapy

100 Deals associated with Apatinib Mesylate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Apatinib Mesylate	L01XE	DB14765

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Germline BRCA-mutated, HER2-negative metastatic breast cancer	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Dec 2024
Hepatocellular Carcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	07 Jan 2021
Gastroesophageal junction adenocarcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	17 Oct 2014
stomach adenocarcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	17 Oct 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic hepatocellular carcinoma	NDA/BLA	United States	Elevar Therapeutics, Inc.	21 Oct 2024
Unresectable Hepatocellular Carcinoma	NDA/BLA	United States	Elevar Therapeutics, Inc.	17 May 2023
Stomach Cancer	NDA/BLA	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	09 Aug 2011
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	21 Sep 2020
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Sep 2020
Advanced Triple-Negative Breast Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Jul 2020
Breast Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	03 Jul 2020
Metastatic breast cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	03 Jul 2020
PD-L1 positive Lung Cancer	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	15 Jun 2020
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	15 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04625803 (Pubmed \| NPJ Precis Oncol)	Phase 2	Colonic Cancer Neoadjuvant	12	mFOLFOX6 plus camrelizumab and apatinib	chctjaywwz(ecwimrtbuc) = nsblwgloqm zwbnzgclmv (xfglpqmgmb ) View more	Positive	01 Apr 2026
NCT03083041 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	210	Apatinib+Camrelizumab (Driver Gene Negative Population)	kqbaowbyqs = oyseyxgjlu cigventoxe (iaodxancng, ifxpkimtze - ryuoqaxxgd) View more	-	03 Mar 2026
				Apatinib+Camrelizumab (Driver Gene Positive Population)	kqbaowbyqs = bjgscuxady cigventoxe (iaodxancng, nbepuqnait - sanascfeeg) View more
NCT04559607 (CHANCE2005, Pubmed \| J Clin Oncol)	Phase 2	Unresectable Hepatocellular Carcinoma	200	TACE combined with camrelizumab and rivoceranib	vpdgyitulw(yemxoflizi) = dacxzcfnae bgiljcsjdz (esrzwdwoar, 8.8 - 13.7) View more	Positive	24 Feb 2026
				TACE alone	vpdgyitulw(yemxoflizi) = vusdxsjkfg bgiljcsjdz (esrzwdwoar, 2.4 - 4.2) View more
NCT03092895 (SHR-1210-II-203, CTgov)	Phase 2	Gallbladder Carcinoma \| Biliary Tract Neoplasms \| Primary Malignant Liver Neoplasm ... View more	157	Apatinib+SHR-1210 (Arm A：SHR-1210+Apatinib)	yyuhksbtki = opnpqwgvii nhbhtwcpaj (apmcbnbulj, ucezprwadh - jxogsappab) View more	-	29 Jan 2026
				FOLFOX4+SHR-1210 (Arm B：Hepatocellular Carcinoma(SHR-1210 + FOLFOX4 Q2W))	yyuhksbtki = jmlbvexdrv nhbhtwcpaj (apmcbnbulj, cupvljgieh - hzjplcknye) View more
NCT05447702 (NeoPanDa03, SABCS2025)	Phase 2	Triple Negative Breast Cancer Neoadjuvant HER2 Negative \| PR Negative \| ER Negative	35	Camrelizumab+apatinib+chemotherapy	xqypliduoi(tpcjrccgmw) = Elevated levels of alanine aminotransferase (38.2%) jdeeorcila (lcxtugthyc ) View more	Positive	11 Dec 2025
ESMO_ASIA2025	Not Applicable	Unresectable Hepatocellular Carcinoma	1,586	TACE + Apatinib	caqpiikcqx(fqoejphdey): HR = 0.42 (95.0% CI, 0.36 - 0.49), P-Value = < 0.00001 View more	Positive	05 Dec 2025
				TACE
NCT03764293 (CARES-310, Pubmed \| Lancet Oncol) Manual	Phase 3	Unresectable Hepatocellular Carcinoma First line	543	Camrelizumab 200 mg + Rivoceranib 250 mg	vkhpuhvivt(zljxrzkcqn) = sdifzxecfz kvklrugmnt (rhhngqynvx, 20.6 - 27.2) View more	Positive	01 Dec 2025
				Sorafenib 400 mg	vkhpuhvivt(zljxrzkcqn) = pmfmjrfjba kvklrugmnt (rhhngqynvx, 13.2 - 18.5) View more
NCT04296370 (FABULOUS, Pubmed \| Lancet Oncol) Manual	Phase 3	Germline BRCA-mutated, HER2-negative metastatic breast cancer HER2 Negative \| BRCA1 Mutation (Germline) \| BRCA2 Mutation (Germline)	203	Fuzuloparib + Apatinib	vkzmaoqzim(yxdpeczhgf) = uykihokpga bjlrsouedw (mryhhrouum, 8.4 - 13.1) View more	Positive	01 Dec 2025
				Fuzuloparib	vkzmaoqzim(yxdpeczhgf) = qsfydfhqnx bjlrsouedw (mryhhrouum, 4.2 - 7.6) View more
NCT04229615 (FZOCUS-1, CA Cancer J Clin) Manual	Phase 3	Ovarian Cancer First line	674	Fuzuloparib + Apatinib	svmzdpqexu(fjqdbadmwu) = royvsnnffu ivmklmdifs (rmvsgokbvk ) View more	Positive	25 Nov 2025
				Fuzuloparib	svmzdpqexu(fjqdbadmwu) = mpnrqydatd ivmklmdifs (rmvsgokbvk ) View more
NCT04521153 (CARES-009, Pubmed \| Lancet) Manual	Phase 2/3	Hepatocellular Carcinoma Neoadjuvant \| Adjuvant	294	Perioperative+ camrelizumab + rivoceranib	gwijnyrzdy(lvxwjqlvuu) = xtgodlqqnu dgzrbedeoa (srgoslauye, 23.2 - NE) View more	Positive	01 Nov 2025
				surgery alone	gwijnyrzdy(lvxwjqlvuu) = vvplblxboc dgzrbedeoa (srgoslauye, 14·9 - NE) View more